Research programme: monoclonal T cell receptor therapeutics - MediGene Ltd

Drug Profile

Research programme: monoclonal T cell receptor therapeutics - MediGene Ltd

Alternative Names: Monoclonal TCRs; mTCRs; SurDex; TaxoDex

Latest Information Update: 15 Dec 2015

Price : $50

At a glance

  • Originator Avidex
  • Developer MediGene Ltd
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Leukaemia
  • Discontinued Bladder cancer; Lung cancer; Pancreatic cancer; Prostate cancer; Viral infections

Most Recent Events

  • 15 Dec 2015 Preclinical trials in Autoimmune disorders in United Kingdom (unspecified route) before December 2015
  • 15 Dec 2015 Preclinical trials in Leukaemia in United Kingdom (unspecified route)
  • 17 Jan 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top